Every year, nearly 5 million adults with cancer are hospitalized. Limited evidence suggests that hospitalization of the cancer patient is associated with adverse morbidity and mortality. Hospitalization of the patient with advanced cancer allows for an intense examination of health status in the face of terminal illness and an opportunity for defining goals of care. This experience-based guide reports what is currently known about the topic and outlines a systematic approach to maximizing opportunities, improving quality, and enhancing the well-being of the hospitalized patient with advanced cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821746 | PMC |
| http://dx.doi.org/10.1002/jhm.2511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Hematology, Lanzhou University Second Hospital, Lanzhou 730000, China. *Corresponding authors, E-mail:
Article Synopsis
- BTLA is an inhibitory immune checkpoint that interacts with HVEM to regulate immune balance and maintain immune tolerance on the same cell, while also affecting different immune cells to suppress immune responses.
- Dysregulation of the BTLA/HVEM interaction can lead to impaired immune cell function, allowing tumor cells to evade immune detection and progress.
- Research indicates that BTLA and HVEM are often abnormally expressed in various tumors, making them potential targets for future immunotherapy approaches in treating hematologic malignancies.
Multi-disciplinary treatment of broncho-esophageal fistula in a high-risk single-lung patient.
J Cardiothorac Surg
January 2025
Section of Cardiothoracic Surgery, Department of Heart Disease, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Background: A broncho-esophageal fistula (BEF) is a medical and surgical disaster. Treatment of BEF is often limited to palliative stent treatment that may migrate or cause erosions and tissue necrosis. Surgical repair of BEF is the only established definite treatment.
View Article and Find Full Text PDFPersonalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.
Acta Neuropathol Commun
January 2025
Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
Glioblastoma (GBM) is a highly aggressive adult brain cancer, characterised by poor prognosis and a dismal five-year survival rate. Despite significant knowledge gains in tumour biology, meaningful advances in patient survival remain elusive. The field of neuro-oncology faces many disease obstacles, one being the paucity of faithful models to advance preclinical research and guide personalised medicine approaches.
View Article and Find Full Text PDFMolecule interacting with CasL-2 enhances tumor progression and alters radiosensitivity in cervical cancer.
J Transl Med
January 2025
Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, No. 467 of Zhongshan Road, Shahekou District, Dalian, 116023, China.
Objective: Cervical cancer is a common malignancy among women, and radiotherapy remains a primary treatment modality across all disease stages. However, resistance to radiotherapy frequently results in treatment failure, highlighting the need to identify novel therapeutic targets to improve clinical outcomes.
Methods: The expression of molecule interacting with CasL-2 (MICAL2) was confirmed in cervical cancer tissues and cell lines through western blotting (WB) and immunohistochemistry (IHC).
Health utility scores of six common cancers in China measured by SF-6Dv2.
Health Qual Life Outcomes
January 2025
School of Health Management, Harbin Medical University, Harbin, 150081, China.
Purpose: Given the recent update of SF-6Dv2, detailed data on utility scores for cancer patients by cancer type remain scarce in China and other regions, which limits the precision of cost-utility analyses (CUA) in cancer interventions. The aim of the study was to systematically evaluate utility scores of six common cancers in China measured using SF-6Dv2, and identify the potential factors associated with utility scores.
Methods: A hospital-based cross-sectional survey was conducted from August 2022 to December 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!